Skip to main content
Premium Trial:

Request an Annual Quote

When Boring Is Good

Getting your genome sequenced or getting genotyped is increasingly within reach for many people, including healthy people, and NBC News' Nancy Snyderman and some of her family members took a dive into their genetics. Snyderman underwent both 23andMe testing and Illumina sequencing.

"What's fascinating ... is that this is me, right here on a tablet," Snyderman tells an NBC colleague. "And as we learn more about what genes underlie specific diseases, I'll have this as a reference."

Scripps Health's Eric Topol and Robert Green from Brigham and Women's Hospital both caution that it is still early days for clinical genome sequencing. "As we roll out genomic medicine we are fighting against this society-wide misconception that having the bad gene means you're going to get the disease. That's only true in a very few cases," Green said.

Still, Anne Wojcicki from 23andMe notes that if people know their genetic information, that can help them manage their health."It's important for you to actually own your own data and be able to give it to your physician, give it to your insurance company, give it to others as you want," she adds. "But it's important for you to own it first."

As for Snyderman, she says that she found her genome to be "boring" — but that's a good thing.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more